Prestige Consumer Healthcare (PBH) to Release Earnings on Thursday

Prestige Consumer Healthcare (NYSE:PBH) will be releasing its earnings data before the market opens on Thursday, August 8th. Analysts expect Prestige Consumer Healthcare to post earnings of $0.87 per share for the quarter. Prestige Consumer Healthcare has set its FY 2025 guidance at 4.400-4.460 EPS and its FY25 guidance at $4.40-$4.46 EPS.Investors that wish to listen to the company’s conference call can do so using this link.

Prestige Consumer Healthcare (NYSE:PBH) last released its quarterly earnings results on Tuesday, May 14th. The company reported $1.02 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.14 by ($0.12). Prestige Consumer Healthcare had a net margin of 18.60% and a return on equity of 13.48%. The firm had revenue of $277.00 million during the quarter, compared to analyst estimates of $287.42 million. During the same period in the prior year, the business earned $1.07 EPS. The business’s revenue for the quarter was down 3.1% compared to the same quarter last year. On average, analysts expect Prestige Consumer Healthcare to post $4 EPS for the current fiscal year and $5 EPS for the next fiscal year.

Prestige Consumer Healthcare Stock Performance

PBH opened at $68.13 on Wednesday. The business’s 50-day moving average price is $67.88 and its two-hundred day moving average price is $68.43. Prestige Consumer Healthcare has a 1 year low of $56.34 and a 1 year high of $75.31. The company has a market capitalization of $3.38 billion, a price-to-earnings ratio of 16.34, a P/E/G ratio of 2.00 and a beta of 0.49. The company has a debt-to-equity ratio of 0.68, a current ratio of 3.20 and a quick ratio of 2.02.

Wall Street Analyst Weigh In

Several research firms have issued reports on PBH. Canaccord Genuity Group reissued a “buy” rating and issued a $80.00 price target on shares of Prestige Consumer Healthcare in a research note on Tuesday, May 21st. DA Davidson raised Prestige Consumer Healthcare from a “neutral” rating to a “buy” rating and lifted their target price for the company from $65.00 to $93.00 in a research report on Friday, June 21st. Finally, StockNews.com downgraded Prestige Consumer Healthcare from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, May 21st. One analyst has rated the stock with a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $98.25.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.